On Tuesday, the US Food and Drug Administration (FDA) approved GSK plc’s (NYSE:GSK) Exdensur (depemokimab-ulaa) as an add-on maintenance treatment of severe asthma characterised by an eosinophilic phenotype in patients aged 12 years and older.



<ul>
<li>GSK stock is approaching key resistance levels. What’s behind GSK new highs?</li>
</ul>



The FDA approval of Exdensur is based on data from the SWIFT-1 and SWIFT-2 phase 3 trials.



<h2>Trial Data</h2>



In these studies, depemokimab demonstrated sustained exacerbation reduction with two doses per year versus placebo, both plus standard of care.



Also Read: GSK Expands Use Of Urinary Tract Infection Drug For Gonorrhoea Patients



Treatment with depemokimab resulted in a significant 58% and 48% reduction in the rate of annualised asthma exacerbations (asthma attacks) over 52 weeks from SWIFT-1 and SWIFT-2, respectively.



In a secondary endpoint from SWIFT-1 and SWIFT-2, patients treated with depemokimab experienced numerically fewer exacerbations requiring hospitalisation and/or emergency department visits (1% and 4%) compared with placebo (8% and 10%), respectively.



A pre-specified pooled analysis of the two trials showed there was a 72% reduction in the annualised rate of clinically significant exacerbations requiring hospitalisation and/or ED visits over 52 weeks for depemokimab compared with placebo.



Depemokimab recently received marketing authorisation from the U.K.’s Medicines and Healthcare products Regulatory Agency and a positive CHMP opinion in Europe, with an approval decision expected in the first quarter of 2026.



GSK Price Action: GSK shares were up 1.21% at $49.37 during premarket trading on Tuesday. The stock is trading near its 52-week high of $49.39, according to Benzinga Pro data.



Read Next:



<ul>
<li>Google DeepMind CEO Warns AI Startup Bubble Is Forming As Early-Stage Firms Raise Tens Of Billions Before Launch</li>
</ul>



Photo by JPC_PROD via Shutterstock

The FDA has approved GSK's Exdensur (depemokimab-ulaa) for severe eosinophilic asthma in patients aged 12 and older, based on Phase 3 trials showing up to 58% fewer asthma attacks with twice-yearly dosing. GSK shares rose 1.21% to $49.37, nearing a 52-week high.

FDA Approves GSK's Drug, Targets Severe Asthma With Two Doses Per Year